Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 8—August 2005

Research

Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use

Conan MacDougall*, Spencer E. Harpe*, J. Patrick Powell*, Christopher K. Johnson†, Michael B. Edmond*, and Ron E. Polk*Comments to Author 
Author affiliations: *Virginia Commonwealth University, Richmond, Virginia, USA; †Idaho State University, Boise, Idaho, USA

Main Article

Table 2

Associations between fluoroquinolone use and resistance in individual years*

FQ use FQ-R P. aeruginosa
MRSA
Total FQ Levofloxacin Ciprofloxacin Total FQ Levofloxacin Ciprofloxacin
1999 R2 0.525 0.593 0.233 0.392 0.644 0.255
p 0.008 12 0.116 0.029 0.0017 0.0937
n 12 0.003 12 12 12 12
2000 R2 0.397 0.285 0.519 0.617 0.617 0.112
p 0.004 0.019 0.348 0.0001 0.0001 0.175
n 19 19 19 18 18 18
2001 R2 0.481 0.335 0.067 0.318 0.32 0.159
p 0.001 0.009 0.2821 0.018 0.018 0.1134
n 19 19 19 17 17 17
2002 R2 0.178 0.112 0.09 0.267 0.28 0.145
p 0.056 0.137 0.184 0.019 0.017 0.097
n 21 21 21 20 20 20
2003 R2 0.104 0.012 0.01 0.157 0.02 0.001
p 0.16 0.641 0.66 0.092 0.538 0.9924
n 20 20 20 19 19 19

*Linear regression of fluoroquinolone (FQ) use versus percent resistance for hospitals. R2, coefficient of determination; n, number of hospitals. Bold indicates significant relationships (p<0.05). FQ-R P. aeruginosa, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.

Main Article

TOP